The decision by Agios Pharmaceuticals Inc. to end work with next-generation oral pyruvate kinase activator tebapivat in sickle cell disease (SCD) put pressure on the company’s first-generation Pyrukynd (mitapivat) and left Novo Nordisk A/S in pole position as the firm advances etavopivat toward an approval bid in the second half of this year.